San Carlos, CA, United States of America

Maria Fardis

This inventor holds 28 USPTO granted patents and 32 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Tumor Infiltrating Lymphocytes. Top assignees: Gilead Sciences, Inc., Iovance Biotherapeutics, Inc., Kosan Biosciences Incorporated. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Maria Fardis. Retrieved from https://idiyas.com/inventor/maria-fardis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 32)

% Patents Active = 60.7

CIPO Patents = 2 (Patent Applications = 20)

EPO Patents = 5 (Patent Applications = 23)

Average Co-Inventor Count = 4.3

ph-index = 12

Forward Citations = 482(Granted Patents)

Location History:

San Carlso, CA (US) (2014)
San Carlos, CA (US) (2003 - 2023)

Company Filing History:

19 out of 946

Gilead Sciences, Inc.

patents

4 out of 110

Iovance Biotherapeutics, Inc.

patents

2 out of 110

Kosan Biosciences Incorporated

Graf Finck Von Finckenstein, Friedrich-Reinhard

patent

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Tumor Infiltrating Lymphocytes

CTLA-4 Inhibitors

PD-1 Inhibitors

AKT Pathway Inhibitors

Antiviral Phosphonate Analogs

Immuno-Modulatory Activity

Anti-Cancer Compounds

Polyketide Derivatives

Kinase Inhibitory Compounds

Metabolic Disease Treatments

HIV Protease Inhibitors

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12678499 - TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS (2026-07-14),

2. 12553029 - TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES (2026-02-17),

3. 12343380 - Expansion of TILs utilizing AKT pathways inhibitors (2025-07-01),

4. 11819517 - Methods of using tumor infiltrating lymphocytes in double-refractory melanoma (2023-11-21),

5. 11433097 - Methods of using tumor infiltrating lymphocytes in double-refractory melanoma (2022-09-06),

6. 9139604 - Antiviral phosphonate analogs (2015-09-22),

7. 8871785 - Antiviral phosphonate analogs (2014-10-28),

8. 8674088 - Antiviral phosphinate compounds (2014-03-18),

9. 8586744 - Antiviral phosphinate compounds (2013-11-19),

10. 8022083 - Antiviral phosphonate analogs (2011-09-20),

11. 7893264 - Antiviral phosphinate compounds (2011-02-22),

12. 7655623 - [object Object] (2010-02-02),

13. 7649015 - Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds (2010-01-19),

14. 7645747 - Therapeutic phosphonate compounds (2010-01-12),

15. 7470724 - Phosphonate compounds having immuno-modulatory activity (2008-12-30),

Title: Maria Fardis: Innovator in Cancer Treatment Patents

Introduction: Maria Fardis, based in San Carlos, California, is a prolific inventor with an impressive portfolio of 25 patents. Her contributions to the field of oncology, particularly in utilizing tumor infiltrating lymphocytes, have significantly advanced treatment methodologies for melanoma, especially in cases resistant to conventional therapies.

Latest Patents: Among her latest innovations, Maria has developed methods for using tumor infiltrating lymphocytes in double-refractory melanoma. This research discloses techniques for treating melanomas that are unresponsive to other forms of therapy. Additionally, she has identified IP-10 as a biomarker to predict treatment efficacy, further enhancing personalized medicine approaches in oncology.

Career Highlights: Maria has an extensive career, having worked with renowned organizations like Gilead Sciences and Kosan Biosciences. Her roles in these companies have allowed her to refine her expertise and contribute significantly to cancer treatment solutions, particularly through her patented inventions.

Collaborations: Throughout her career, Maria has collaborated with notable professionals in the field, including Aesop Cho and Xiaowu Chen. These collaborations have fostered innovation and knowledge exchange, driving forward advancements in cancer therapies.

Conclusion: Maria Fardis continues to be an influential figure in cancer research and patented innovation. Her work not only addresses pressing medical challenges but also enhances treatment options available to patients suffering from double-refractory melanoma. As her career progresses, the scientific community eagerly anticipates her future contributions to the field.

Profile summary based on public USPTO records.